baber/WOPTO huggingface dataset:
Patent NZ-570849-A (NZ)
Title: New citrate salt of an indole derivative and its pharmaceutical use
Inventor: BERG ANNA-LENA
IPC: A61K31/4439
Filed: 2007-01-31
Abstract: Disclosed is the citrate salt of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile (the compound of formula 1). Also disclosed is the above salt in crystalline form. Also disclosed is a process for preparing the above salt or crystal form. Also disclosed is the use of the above salt for treating cognitive disorders, dementia, Cognitive Deficit in Schizophrenia, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, Frontotemporal dementia, Frontotemporal dementia Parkinson's Type, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, corticobasal degeneration, traumatic brain injury, dementia pugilistica, Alzheimer's Disease, Down's syndrome, vascular dementia, Parkinson's Disease, postencephelatic parkinsonism, dementia with Lewy bodies, HIV dementia, Huntington's Disease, amyotrophic lateral sclerosis, motor neuron diseases, Creuztfeld-Jacob's disease, prion diseases, attention deficit disorder, attention deficit hyperactivity disorder, affective disorders, Bipolar Disorder including acute mania, bipolar depression, bipolar maintenance, major depressive disorders including depression, major depression, mood stabilization, schizoaffective disorders including schizophrenia, dysthymia, bone related disorders or conditions, osteoporosis, and for increasing bone formation, increasing cancellous bone formation and/or new bone formation, increasing bone mineral density, reducing the incidence of fracture or enhancing fracture healing.
Patent NZ-571429-A (NZ)
Title: Purine derivatives for use as adenosine A2A receptor agonists
Inventor: FAIRHURST ROBIN ALEC
IPC: A61K31/7076
Filed: 2007-04-19
Abstract: Disclosed is a substituted purine compound of formula (I) where R1 is carbamic acid methyl ester or propionamide and R2 with the nitrogen it is attached to is 2,2-diphenyl-ethylamino. R3 is as disclosed in the description. Also disclosed is a pharmaceutical composition or a pharmaceutical combination comprising a compound of formula (I) and the use of a compound of formula (I in the manufacture of a medicament for treating a condition mediated by adenosine A2A receptor, an inflammatory disease or obstructive airways disease. Examples of compounds of formula (I) are: ((1S,2R,3S,4R)-4-{ 6-(2,2-Diphenyl-ethylamino)-2-[(R)-3-(3-pyridin-3-yl-ureido)-pyrrolidin-1-yl]-purin-9-yl} -2,3-dihydroxy-cyclopentyl)-carbamic acid methyl ester; ((1S,2R,3S,4R)-4-{ 6-(2,2-Diphenyl-ethylamino)-2-[(R)-3-((R)-3-pyrrolidin-3-ylureido)-pyrrolidin-1-yl]-purin-9-yl} -2,3-dihydroxy-cyclopentyl)-carbamic acid methyl ester; N-((1S,2R,3S,4R)-4-{ 6-(2,2-Diphenyl-ethylamino)-2-[(R)-3-(3-phenyl-ureido)-pyrrolidin-1-yl]-purin-9-yl} -2,3-dihydroxy-cyclopentyl)-propionamide and N-[(1S,2R,3S,4R)-4-(6-(2,2-Diphenyl-ethylamino)-2-{ (R)-3-[3-(3-hydroxy-phenyl)-ureido]-pyrrolidin-1-yl} -purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide.
Patent NZ-573424-A (NZ)
Title: NEW FORM OF ADMINISTRATION OF RACECADOTRIL WHICH IS ALSO KNOWN AS acetorphan OR benzyl (RS)-[[2-[(acetylsulphanyl)methyl]-3-phenylpropanoyl]amino]acetate
Inventor: SCHWARTZ JEAN-CHARLES
IPC: A61P1/12
Filed: 2007-05-14
Abstract: Disclosed is a racecadotril tablet consisting of a coated core, said core containing racecadotril, wherein the core comprises, by weight: 20 to 50 percent racecadotril; 25 to 50 percent filler(s); 9 to 25 percent disintegrant(s); 2 to 10 percent binding agent(s); 0.5 to 5 percent lubricant(s). Also disclosed is the process for making the tablet and the use of racecadotril for the manufacture of a medicament for treating diarrhoea.
Patent NZ-576040-A (NZ)
Title: High affinity human antibodies to human il-4 receptor
Inventor: STEVENS SEAN
IPC: A61K39/395
Filed: 2007-10-02
Abstract: Disclosed is an antibody or antigen-binding fragment thereof, that specifically binds hIL-4R shown as SEQ ID NO: 1, with a KD of about 200pM or less, as measured by surface Plasmon resonance, comprising the heavy chain CDR1, CDR2 and CDR3 amino acid sequence from SEQ ID NO: 579 or 581, and the light chain CDR1, CDR2 and CDR3 amino acid sequence from SEQ ID NO: 59. Further disclosed are isolated nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host-vector systems and methods of use thereof.
Patent NZ-576082-A (NZ)
Title: Compositions and methods for therapy and diagnosis of cancer and cancer metastasis involving tpte and cxcr4 expression
Inventor: SAHIN UGUR
IPC: C12Q1/68
Filed: 2007-10-09
Abstract: Disclosed is a method for diagnosing, monitoring and/or prognosing the metastatic behaviour of cancer regarding the occurrence of distant metastasis in a patient comprising determining the level of expression of TPTE and CXCR4. The level of expression of TPTE and a level of expression of CXCR4 is increased compared to the level of expression in a subject without metastasis of cancer or without a risk for metastasis of cancer is indicative for a metastatic behaviour of cancer regarding the occurrence of distant metastasis or for a potential for a metastatic behaviour of cancer regarding the occurrence of distant metastasis.
Patent NZ-576800-A (NZ)
Title: Optimized non-canonical zinc finger proteins
Inventor: CAI QIHUA C
IPC: C07K14/00
Filed: 2007-12-13
Abstract: 576800 Provided is a synthetic or recombinant zinc finger protein comprising at least one non-C2H2 zinc finger, wherein the non-C2H2 zinc finger has four zinc coordinating residues and a helical portion comprising a recognition helix region involved in DNA binding and a zinc coordinating region, and further wherein the zinc-coordinating region of the helical portion comprises the amino acid sequence HAQRCXL and wherein the recognition helix region is engineered to bind a target sequence in DNA. The target sequence can be IPP2K gene used to making a transgenic plant with more metabolically available phosphorus in seed of maize, rice, wheat, potato, soybean, tomato, tobacco, members of the Brassica family, and Arabidopsis.
Patent NZ-583002-A (NZ)
Title: Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation
Inventor: YOSHINAGA STEVEN KIYOSHI
IPC: A61K48/00
Filed: 2000-01-27
Abstract: This patent discloses the use of a B7RP-1 polypeptide in the preparation of a medicament for (i) increasing an immune response, (ii) cancer immunotherapy and (iii) use as a vaccine adjuvant.
Patent NZ-586192-A (NZ)
Title: Adaptor for a fastening tool used for holding brackets in position for attachment to a surface
Inventor: GOSIS ANATOLY
IPC: B25C7/00
Filed: 2008-10-15
Abstract: 586192 A holding bracket 50 for attachment to a fastening tool, where the fastening tool defines a major axis and has a barrel for firing a fastener, the tool defining a major axis. The holding bracket 50 holds overlapping portions of two members to be fastened to one another. The bracket 50 comprises a mounting portion 52 configured for attachment to the tool, an extension portion extending from and non-pivotally attached to the mounting portion 52, and a holding arm 56. The holding arm 56 is attached to the extension portion and spaced apart from the mounting portion 52 in the direction of the tool major axis such that the mounting portion 52 and the holding arm 56 are parallel and define a gap between the holding arm 56 and the mounting portion 52. The holding arm 56 has two angled sides and a generally triangular-shaped cross-section formed by the two angled sides. The gap is configured for holding the overlapping portions of the two members for insertion of a fastener ejected from the barrel.
Patent NZ-587101-A (NZ)
Title: Matching call centre agents with callers by using a pattern matching algorithm and a potential for a selected interaction for each agent-caller match
Inventor: CHISHTI ZIA
IPC: H04M3/523
Filed: 2008-09-19
Abstract: 587101 Disclosed is a method for operating a call-center. Caller data is obtained (501) by one or more computers for each of a set of callers. The data includes one or more data elements selected from demographic data and/or psychographic data of the caller. Agent data for each of a set of agents is then obtained (502) by the one or more computers. This data includes one or more data elements selected from demographic data and/or psychographic data of the agent. Each agent of the set of agents is matched using a pattern matching algorithm (504) to each caller of the set of callers, in a pair-wise fashion, to determine a potential for a selected interaction for each agent-caller match based at least in part on the demographic data and/or the psychographic data. One of the agents of the set of agents is then connected (505) to one of the callers of the set of callers based at least in part on results of the pattern matching algorithm.
Patent NZ-587749-A (NZ)
Title: An aerodynamic vehicle cross bar having projections with notches
Inventor: HUBBARD PETER DOUGLAS
IPC: B60R9/04
Filed: 2010-09-02
Abstract: A roof rack cross bar is disclosed. The roof rack cross bar has an approximately rectangular cross section where: (a) the leading face of the cross bar, as it is fitted to a vehicle, is shaped to have an upper and lower forward facing projection; (b) the projections have a plurality of notches that direct air flow around the bar thereby reducing audible noise produced by the cross bar; (c) the region intermediate the two projections is slightly recessed so as to form a groove intermediate the two projections; and (d) the transition between the groove and projections is smooth and the groove presents a concave surface to the airflow.
Patent NZ-590830-A (NZ)
Title: A control system coupled to a physical process for calculating and plotting statistical data
Inventor: RAMSAY LAWSON H
IPC: G05B15/02
Filed: 2009-07-15
Abstract: A control system comprises a processing unit configured to monitor and control a physical process external to the processing unit (16); a flow computer (18) coupled to the processing unit; a historian unit (22) coupled to the flow computer by way of a computer network ; and a human/machine interface (HMI) (28) coupled to the historian unit by way of the computer network. The flow computer is configured to monitor the physical process external to the processing unit. The historian unit is configured to receive data regarding the physical process, and configured to store the data in a nonvolatile storage device and the HMI is configured to retrieve historical data values regarding the physical process from the historian unit; and then calculate statistical data not held in the historian unit. The calculation is based on the historical data values. The HMI is further configured to plot the statistical data not held in the historian unit with the plotting on a display device.
Patent NZ-593948-A (NZ)
Title: Enzyme preparations yielding a clean taste
Inventor: DE SWAAF MAXIMILIAAN PETER MARIE
IPC: A23L5/20
Filed: 2006-11-28
Abstract: NZ 593948 Disclosed is a process to produce a modified dairy product which comprises treating a dairy product with a preparation of a neutral lactase from Kluyveromyces which comprises less than 30 units of arylsulfatase activity per Neutral Lactase Unit (NLU) of lactase activity. Also disclosed is a dairy product produced by said process.
Patent NZ-596218-A (NZ)
Title: Bssl antagonists for treatment of inflammatory diseases
Inventor: HERNELL OLLE
IPC: A61K39/395
Filed: 2010-04-06
Abstract: NZ 596218 Disclosed is the use of an antibody or an antibody fragment that specifically binds to human BSSL in the manufacture of a pharmaceutical composition for the prevention, prophylaxis and/or treatment of an inflammatory disease.
Patent NZ-598453-A (NZ)
Title: Method for thermal management of an electric power conversion installation and installation for implementing the method
Inventor: MOREAU JULIEN
IPC: F24F11/76
Filed: 2012-02-28
Abstract: 598453 Disclosed is an operating method for the cooling of an electric power conversion installation. The installation in which the method is performed comprises an enclosure in which a voltage converter and a power electronics device are arranged. The method is performed by implementing different routings of a heat transfer fluid according to an operating state of the power electronics device and/or according to a thermal environment in which the installation is located. An apparatus for performing this method is also disclosed.
Patent NZ-599446-A (NZ)
Title: Novel substituted imidazoquinolines
Inventor: GEKELER VOLKER
IPC: A61K31/4353
Filed: 2009-03-23
Abstract: 599446 Disclosed is a compound of formula (I) where the substituents are as disclosed in the specification. Examples of compound of formula (I) are: 2-ethyl-1-[4-(tetrahydro-2H-pyran-4-ylamino)butyl]-1H-imidazo[4,5-c]quinolin-4-amine, 1-[4-(1-azabicyclo[2.2.2]oct-3-ylamino)butyl]-2-ethyl-1H-imidazo[4,5-c]quinolin-4-amine and1-{ 4-[(1,1-dioxido-3,4-dihydro-2H-thiochromen-4-yl)amino]butyl} -2-ethyl-1Himidazo[4,5-c]quinolin-4-amine. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for activation of TLR7, treating viral or neoplastic disease or cancer and for the use as an immune response modifier; to stimulate natural killer cell activity, activate macrophages, cause proliferation and differentiation of B-lymphocytes; as a vaccine adjuvant for cell mediated immunity; or to enhance or stimulate the healing of wounds, including chronic wounds.
Patent NZ-608685-A (NZ)
Title: Novel method of preparing benzoimidazole derivatives
Inventor: KIM IN WOO
IPC: C07D471/04
Filed: 2011-09-27
Abstract: The disclosure relates to a method of preparing a benzoimidazole or imidazopyridine derivative of the formula shown herein. In this formula, X and Y are either N or a substituted carbon, R1 is a substituted phenyl, R2 and R3 are either hydrogen or collectively a benzene ring, R4 is a halogen, substituted alkyl or morpholine ring. The method is either a two or three step scheme that contains a benzaldehyde intermediate. This family of compounds are antagonists against the vanilloid reactor-1, which may be involved in pain delivery and various disease states.
Patent NZ-608971-A (NZ)
Title: Method for the preparation of (3s,3s’) 4,4’-disulfanediylbis (3-aminobutane 1-sulfonic acid)
Inventor: BALAVOINE FABRICE
IPC: C07C309/14
Filed: 2011-10-07
Abstract: Disclosed is a process for preparing (3S,3S’) 4,4’-disulfanediylbis(3-aminobutane-1-sulfonic acid) / (3S,3S’) 4,4’-dithiobis(3-amino-butane-1-sulfonic acid) comprising the steps of: (a) reducing (S) ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate to give (S) neopentyl 3-(benzyloxycarbonylamino)-4-hydroxybutane-1-sulfonate; (b) reacting the product of (a) with methanesulfonic anhydride or methanesulfonyl chloride in presence of a base to give (S) neopentyl 3-(benzyloxycarbonylamino)-4-(methylsulfonyloxy)butane-1-sulfonate; (c) reacting the product of (b) with potassium thioacetate to give (S) 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butyl-thioacetate; (d) dimerizing the product of (c) to give (3S,3S’) neopentyl 4,4’-disulfanediylbis(3-(benzyloxycarbonylamino)butane-1-sulfonate); and (e) deprotecting the product of (d) to give (3S,3S’) 4,4’-disulfanediylbis(3-aminobutane-1-sulphonic acid). Also disclosed is crystalline (3S,3S’) 4,4’-dithiobis(3-amino-butane-1-sulfonic acid) trihydrate.
Patent NZ-620542-A (NZ)
Title: Use of organic compound for the treatment of noonan syndrome
Inventor: GU JESSIE
IPC: A61K31/166
Filed: 2012-08-29
Abstract: Disclosed is the use of MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide of Formula (I) for the preparation of a medicament for the treatment of Noonan Syndrome. Also disclosed is a method of treating a warm-blooded non-human animal having Noonan Syndrome, comprising administering to said non animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I).
Patent NZ-623476-A (NZ)
Title: Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Inventor: DE FOUGEROLLES ANTONIN
IPC: C07H21/04
Filed: 2012-10-03
Abstract: Discloses an isolated mRNA encoding a polypeptide of interest, said isolated mRNA comprising: (a) a sequence of n number of linked nucleosides, (b) a 5’ UTR, (c) a 3’ UTR, and (d) at least one 5′ cap structure, wherein said isolated mRNA is fully modified with 1-methylpseudouridine, wherein said isolated mRNA, when administered to peripheral blood mononuclear cells (PBMCs), provides Protein:Cytokine (P:C) ratios of greater than 100 for TNF alpha and greater than 100 for IFNalpha after about eighteen or more hours, and wherein said P:C ratios are higher than those of a corresponding mRNA comprising pseudouridine (ψ) in place of 1-methylpseudouridine.
Patent NZ-626695-A (NZ)
Title: A yarn comprising gel-forming filaments or fibres
Inventor: BONNEFIN WAYNE
IPC: D06M23/10
Filed: 2012-11-29
Abstract: A yarn comprising a blend of from 50% to 100% by weight gel-forming fibres and 0% to 50% by weight textile fibres. The individual fibres are carded to form a continuous web, the web is drawn to produce a sliver and the sliver is rotor-spun into yarn.
Patent NZ-626702-A (NZ)
Title: Methods of pest control in soybean
Inventor: VOCK CHRISTOPH
IPC: A01P7/04
Filed: 2012-02-01
Abstract: The disclosure relates to a method of applying a compound of formula (III) to a crop of soybean plants, the locus thereof, or propagation material thereof, for controlling and/or preventing infestation of the soybean crop by stinkbugs. The stinkbug may be Nezara viridula, Piezodorus spp., Acrosternum spp or Euchistus heros. The compound may be applied in combination with an attractant selected from glucose, saccharose, salt, glutamate, citric acid, soybean oil, peanut oil and soybean milk.
Patent NZ-630278-A (NZ)
Title: Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
Inventor: MANIE ELODIE
IPC: C12Q1/68
Filed: 2013-06-06
Abstract: Disclosed is a method for predicting deficiency in the DNA homologous recombination (HR) pathway in a patient suffering from cancer, comprising the step of quantifying the number of rearrangements in the genomic DNA of a tumour sample obtained from said patient, wherein the number of rearrangements corresponds to the number, per genome, of breakpoints resulting in segments of at least 3 megabases, further comprising the step of comparing the number of rearrangements per genome to a threshold, wherein a number of rearrangements per genome superior to said threshold is indicative of HR deficiency.
Patent NZ-709199-A (NZ)
Title: Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
Inventor: JOHNSON MICHAEL
IPC: C07D241/32
Filed: 2013-12-16
Abstract: The present invention relates to the compound of the formula (I) or pharmaceutically acceptable salts thereof, wherein R1 is arylalkyl or aryloxyalkyl (as further defined herein), as well as compositions containing the same, and processes for the preparation of the same. Therapeutic methods of use thereof are disclosed. The compound and pharmaceutically acceptable salts may be useful as sodium channel blockers and, particularly, in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
Patent NZ-712497-A (NZ)
Title: Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
Inventor: APT KIRK E
IPC: C12R1/89
Filed: 2012-07-20
Abstract: Disclosed is a method of making a biomass of a microorganism having fatty acids and a concentration of EPA, comprising: (a) fermenting the microorganism in a fermenter vessel to produce a biomass wherein the microorganism comprises a Thraustochytrid that produces a biomass having at least 3% EPA of the total weight of the fatty acids; and (b) adjusting the amount of the biomass in the vessel to attain a desired EPA level in the biomass. Also disclosed is an oil extracted from the biomass and its use in a feed product.
Patent NZ-722056-A (NZ)
Title: A vegetation cutter
Inventor: BOYLE NATHAN
IPC: A01D101/00
Filed: 2014-12-19
Abstract: A vegetation cutter is disclosed. Conventional vehicle-mounted mowers or slashers do not allow for the cutting of vegetation close to posts, with attempts to do so often resulting in damage or destruction of the posts. As such, it is often necessary for people to subsequently walk the route with whipper snippers and/or chemical vegetation spray management units to remove the remaining vegetation. The disclosed vegetation cutter cuts vegetation circumferent an obstacle in a single operation – therefore avoiding a second (often labour intensive) operation to remove such vegetation. The vegetation cutter (800) comprises a frame (802) comprising a dock (806) for receiving the obstacle. A member (see 818, figure 6) that is substantially planar, circular in shape, and has an object-receiving inner channel (822), is rotatably movable relative to the frame (802). At least one cutter (see 820a, 820b, 820c, figure 6) depends from the member. In use, a post is received in the inner channel and the frame (802) of the vegetation cutter remains stationary as the member rotates, circumferentially moving the cutter about the periphery of the tree/post (see also figure 8). The provision of the member (see 818, figure 6) enables two or three cutters (see 820a, 820b, 820c, figure 6) to be carried and therefore can be used to cut wide swathes of vegetation as well as provide an even balance during operation.
Patent NZ-724870-A (NZ)
Title: Antibodies that bind human cannabinoid 1 (cb1) receptor
Inventor: KRETZ-ROMMEL ANKE
IPC: C07K16/28
Filed: 2015-03-27
Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
Patent NZ-736510-A (NZ)
Title: Package, packaged product, method of releasing at least one agent into chamber portion of package, and process of packaging
Inventor: PALUMBO RICCARDO
IPC: B65D81/32
Filed: 2016-04-27
Abstract: There exists a trend of increased consumer attention to food product safety reduction of food waste. There also exists a trend of consumers wanting to confer a specific aroma to a product without the need for additional packaging. A package (10) includes a chamber portion (12), a hollow frame (14) adjacent to the chamber portion, and a frangible chamber closure zone (22) between the chamber portion and the frame. A method of releasing at least one agent into a chamber portion (12) of a package includes rupturing a frangible closure (22) between the chamber portion (12) and a hollow frame (14) to release the at least one agent contained in the hollow frame into the chamber portion. A process of packaging includes providing a base web; placing a product (16) on the base web (40); positioning over the product a lid web (38); fixing the lid web to the base web to form a chamber portion (12) enclosing the product; fixing the lid web (38) to the base web (40) to form a hollow frame (14) adjacent to the chamber portion (12); and including an agent in the frame (14).